ArriVent BioPharma (AVBP) Stock Price, News & Analysis

Company Overview

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing precision oncology therapies for patients with genetically defined cancers. The company’s primary focus is on targeted treatments for non-small cell lung cancer (NSCLC), particularly tumors driven by mutations in the epidermal growth factor receptor (EGFR) gene.

ArriVent’s lead product candidate is furmonertinib, an oral, irreversible EGFR tyrosine kinase inhibitor designed to target a range of EGFR mutations, including common mutations and exon 20 insertion mutations. Furmonertinib has been approved in China for certain patients with EGFR-mutated locally advanced or metastatic NSCLC. ArriVent is evaluating the therapy in clinical studies intended to support potential approvals in additional markets and indications, including the United States.

The company was established to advance innovative medicines developed in other regions for patients worldwide. ArriVent obtained rights to develop and commercialize furmonertinib outside China through a collaboration with Allist Pharmaceuticals, the drug’s developer in China. ArriVent is headquartered in Philadelphia and is led by a biotechnology management team with experience in drug development, oncology and commercialization.

Key Stats

• Today's Range: $12.47 to $13.57
• 50-Day Range: $13.02 to $31.35
• 52-Week Range: $11.36 to $35.83
• Volume: 555,337 shs
• Average Volume: 734,791 shs
• Market Capitalization: $645.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.56
• Consensus Rating: Moderate Buy

ArriVent BioPharma Stock Analysis - MarketRank™

ArriVent BioPharma scored higher than 71% of companies evaluated by MarketBeat, and ranked 220th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ArriVent BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 9 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

ArriVent BioPharma has a consensus price target of $24.56, representing about 88.5% upside from its current price of $13.02.

Amount of Analyst Coverage

ArriVent BioPharma has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ArriVent BioPharma are expected to grow in the coming year, from ($4.04) to ($3.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ArriVent BioPharma is -3.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ArriVent BioPharma is -3.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ArriVent BioPharma has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

15.10% of the float of ArriVent BioPharma has been sold short.

Short Interest Ratio / Days to Cover

ArriVent BioPharma has a short interest ratio ("days to cover") of 2.23, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ArriVent BioPharma has recently decreased by 19.46%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ArriVent BioPharma does not currently pay a dividend.

Dividend Growth

ArriVent BioPharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.14

News Sentiment

ArriVent BioPharma has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for ArriVent BioPharma this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for AVBP on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ArriVent BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.58% of the stock of ArriVent BioPharma is held by insiders.

Percentage Held by Institutions

9.48% of the stock of ArriVent BioPharma is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 11/04/2026
• Next Earnings (Estimated): 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AVBP
• Previous Symbol: NASDAQ:AVBP
• CIK: 1868279
• Web: www.arrivent.com
• Phone: 628-277-4836
• Fax: N/A
• Employees: 77
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ArriVent BioPharma: $24.56
• High Price Target: $30.00
• Low Price Target: $18.00
• Potential Upside/Downside: +89.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$166.31 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -50.26%
• Return on Assets: -46.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.16
• Quick Ratio: 14.16

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.44 per share
• Price / Book: 1.74

Miscellaneous

• Outstanding Shares: 49,310,000
• Free Float: 45,077,000
• Market Cap: $640.04 million
• Optionable: Optionable
• Beta: 1.66